scholarly journals Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials

2016 ◽  
Vol 138 (9) ◽  
pp. 2293-2299 ◽  
Author(s):  
Michael J. Sorich ◽  
Ganessan Kichenadasse ◽  
Andrew Rowland ◽  
Richard J. Woodman ◽  
Arduino A. Mangoni
Keyword(s):  
Renal Cell Carcinoma ◽  
Clinical Trials ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Secondary Analysis ◽  
Angiotensin System

scholarly journals Impact of Geographic Regions on Overall Survival in Patients With Metastatic Renal Cell Carcinoma: Results From an International Clinical Trials Database

2018 ◽  
pp. 1-14
Author(s):  
Andre P. Fay ◽  
Rana R. McKay ◽  
Xun Lin ◽  
Ronit Simantov ◽  
Toni K. Choueiri
Keyword(s):  
Renal Cell Carcinoma ◽  
Overall Survival ◽  
Clinical Trials ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Geographic Region ◽  
Univariable Analysis ◽  
Geographic Regions

Purpose Health determinants vary according to geographic region and may affect the outcomes of patients with metastatic renal cell carcinoma (mRCC) treated during clinical trials of targeted therapy. Here, we investigate the overall survival (OS) of patients with mRCC treated in the era of targeted therapy by geographic region. Methods We conducted a pooled analysis of patients with mRCC who were treated during phase II or III clinical trials. Clinical characteristics and survival data were collected. Statistical analyses were performed with the Kaplan-Meier method and log-rank test in univariable analysis. Results Overall, 4,736 patients were included in the analysis. Patient characteristics differed according to geographic region. No statistically significant differences in OS were observed when the United States/Canada (USC) was compared with the following other regions: Latin America, Asia/Oceania/Africa, and Eastern Europe. In a univariable analysis, OS differed among patients enrolled in trials in USC compared with Western Europe (20.3 v 17.4 months; hazard ratio, 1.15; 95% CI, 1.03 to 1.3; P = .015), but it did not differ in a multivariable analysis. All-grade treatment-related adverse events (AEs) were observed more frequently in USC. There were no significant differences in grade 3 to 5 AEs among groups. Conclusion Despite different baseline characteristics, OS was similar among patients enrolled in clinical trials across different geographic regions. Access to clinical trials as well as disease biology, AE reporting, and quality of care may contribute to potential differences in outcomes.

Therapeutic Drug Monitoring of Targeted Therapy in Metastatic Renal Cell Carcinoma

2018 ◽  
Vol 25 (6) ◽  
pp. 528-533
Author(s):  
Dehua Liao ◽  
Dangang Shangguan ◽  
Dunwu Yao ◽  
Qing Zhu ◽  
Lizhi Cao ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Targeted Therapy ◽  
Therapeutic Drug Monitoring ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Drug Monitoring ◽  
Renal Cell ◽  
Therapeutic Drug

Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era

2021 ◽  
Author(s):  
Sei Naito ◽  
Tomoyuki Kato ◽  
Kazuyuki Numakura ◽  
Shingo Hatakeyama ◽  
Tomoyuki Koguchi ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell

Impact of metastasectomy on prognosis in patients treated with targeted therapy for metastatic renal cell carcinoma

2016 ◽  
Vol 142 (11) ◽  
pp. 2331-2338 ◽  
Author(s):  
Dalsan You ◽  
Chunwoo Lee ◽  
In Gab Jeong ◽  
Cheryn Song ◽  
Jae-Lyun Lee ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell

Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials

2021 ◽  
Vol 154 ◽  
pp. 120-127
Author(s):  
Francesco Massari ◽  
Alessandro Rizzo ◽  
Veronica Mollica ◽  
Matteo Rosellini ◽  
Andrea Marchetti ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Clinical Trials ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Meta Analysis ◽  
Randomised Clinical Trials
Sign in / Sign up

Export Citation Format

Share Document